BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19563510)

  • 1. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
    Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
    Fundam Clin Pharmacol; 2009 Oct; 23(5):595-600. PubMed ID: 19563510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR; Engstrand S; Berglin E; Johnson O
    Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
    Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
    Clin Exp Rheumatol; 2010; 28(6):880-3. PubMed ID: 21122270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 13. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
    Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
    Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
    J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M; Creemers MC; van Riel PL
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.